novo nordisk - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,840 +0.84%

DJIA 48,336 +0.89%

Nasdaq 25,093 +0.80%

DAX 23,932 -0.13%

Gold $4,196 +0.16%

Oil $95.59 -1.13%

BTC $72,398 +1.44%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

S&P 500 6,840 +0.84%

DJIA 48,336 +0.89%

Nasdaq 25,093 +0.80%

DAX 23,932 -0.13%

Gold $4,196 +0.16%

Oil $95.59 -1.13%

BTC $72,398 +1.44%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

novo nordisk

Eli Lilly Weight-Loss Strategy illustrated by GLP-1 drug research lab with injectables and oral pills

Pharma & Healthcare·Stocks·USA

Eli Lilly Weight-Loss Strategy vs Novo: Price War Shock

By Maik Kemper • Apr 7, 2026

Novo Nordisk Wegovy Strategy illustrated with GLP-1 injection pen and obesity pill on clinical desk

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Wegovy Strategy Boom With HD Dose Push

By Maik Kemper • Apr 7, 2026

Telehealth users explore Hims & Hers GLP-1 partnership weight-loss options on a digital platform

Pharma & Healthcare·Stocks·USA

Hims & Hers GLP-1 partnership sparks new weight-loss boom

By Maik Kemper • Mar 26, 2026

Novo Nordisk Hims partnership GLP-1 drugs Wegovy and Ozempic showcased as premium treatment options

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Hims partnership Boom: GLP‑1 market power shift

By Maik Kemper • Mar 9, 2026

Hims & Hers Novo Nordisk deal sparks sharp HIMS stock surge on GLP-1 obesity drug partnership

Pharma & Healthcare·Stocks·USA

Hims & Hers Novo Nordisk deal sparks 44% premarket surge

By Maik Kemper • Mar 9, 2026

Can the new Hims & Hers Novo Nordisk deal really turn an 80% stock collapse into a long-term GLP-1 comeback story? How big is the…